Pfizer Inc

NYSE: PFE
$24.80
-$1.22 (-4.7%)
Closing Price on November 15, 2024

PFE Articles

24/7 Wall St. has put together a preview of Exxon, Apple, Pfizer and other the Dow Jones Industrial Average companies scheduled to report their quarterly results this week.
Intel, Pfizer, 3M, and Disney launched the DJIA to a solid gain Friday.
The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Apple indicated that it will pay $38 billion in repatriation taxes under the new tax law. Apple says that it is already the largest U.S. taxpayer and that a payment of that size likely would be the...
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
UnitedHealth, Disney, Pfizer, and General Electric were Monday's laggards among the DJIA stocks.
For the Jones Industrial Average to make its 2018 targets, Pfizer and Merck will to have to do their part to help. But they both lagged the markets in 2017.
Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer.
Here is a consensus forecast of each of the 30 Dow Jones Industrial stocks, including a forward 12-month consensus analyst price target and an expected 2018 total return on each.
The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
One strategy that has been popular each year as investors rebalance and make changes is the so-called Dogs of the Dow.
Disney, Pfizer, General Electric, and McDonald's weighed on the DJIA Wednesday.
Pfizer has just raised its payout by about 6% and more than doubled what it already had on its buyback plans.
Intel, Microsoft, Pfizer, and United Technologies drove the DJIA higher Friday.
Shares of Pfizer appeared to be headed for a new high after the company announced that the FDA had approved its treatment for adult patients with active psoriatic arthritis.